Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease?

Abstract Similar risk reduction but fewer side effects would predict more uptake and compliance with low (5 mg) versus full (20 mg) dose tamoxifen. Benefit with low dose is demonstrated for perimenopausal/postmenopausal women with intraepithelial neoplasia and high lesion Ki-67. Longer follow-up needed to determine benefit with low lesion Ki-67. See related article by DeCensi et al., p. 3576